HIV Now: New and Emerging First-line ART Strategies

Expert faculty provide insights on the latest data from studies evaluating recently approved and newly emerging regimens for first-line ART and assess how these new options may fit into evolving HIV treatment paradigms.
Eric S. Daar, MD
Daniel R. Kuritzkes, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 426 KB
Released: December 19, 2018

Acknowledgements

Provided by Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by an educational grant from
Gilead Sciences

Related Content

Multimedia module from Clinical Care Options: HIV experts weigh in on selecting first-line ART and modifying ART for those with virologic suppression

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Eric S. Daar, MD W. David Hardy, MD Babafemi Taiwo, MBBS
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: September 18, 2020 Expired: September 17, 2021

Expert discussion of data from AIDS 2020: Virtual on new and established HIV treatment from Drs Lisa Hightow-Weidman and David Wohl, reported by CCO

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Lisa Hightow-Weidman, MD, MPH David A. Wohl, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: September 11, 2020 Expired: September 10, 2021

Download CCO slides reviewing new HIV data from AIDS 2020 on current ART, long-acting treatment, metabolic effects, COVID-19/HIV, and HIV prevention

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP David A. Wohl, MD
Released: September 8, 2020

Comentarios de CCO emitidos por el Dr. José Arribas sobre los nuevos datos de AIDS 2020: Virtual que evalúa las estrategias óptimas de TAR en los tratamientos de primera y segunda línea

José R. Arribas, MD Released: September 8, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?